Search research articles
Contact Us
Filters
Showing results (31-40 of 182) with videos related to
Page
of 19
Sort By:
JAMA Network Open
|
December 21, 2019
Determining Levers of Cost-effectiveness for Screening Infants at High Risk for Peanut Sensitization Before Early Peanut Introduction
Matthew Greenhawt, Marcus Shaker
JAMA Network Open
|
May 4, 2019
Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis
Marcus Shaker, Matthew Greenhawt
Current Opinion in Pediatrics
|
September 1, 2012
An update on hereditary angioedema
Derek Hsu, Marcus Shaker
JAMA Pediatrics
|
June 11, 2019
Benefits of Stock Epinephrine Likely Misestimated-Reply
Marcus Shaker, Matthew Greenhawt
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
May 26, 2019
A primer on cost-effectiveness in the allergy clinic
Marcus Shaker, Matthew Greenhawt
Pediatrics
|
December 2, 2024
Interaction Between Baseline Participant Factors and Treatment Effects Following Peanut Oral Immunotherapy
Alexandra Conway, Marcus Shaker
Pediatrics
|
December 2, 2024
Altered Symptom Perception in Children With Asthma Is Associated With Poor Childhood Opportunity and Adverse Outcomes
Chaitanya Maddukuri, Marcus Shaker
The Journal of Allergy and Clinical Immunology. in Practice
|
May 12, 2018
The Health and Economic Outcomes of Peanut Allergy Management Practices
Marcus Shaker, Matthew Greenhawt
Current Opinion in Allergy and Clinical Immunology
|
August 5, 2016
An update on ocular allergy
Marcus Shaker, Erin Salcone
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
December 4, 2022
The known knowns, known unknowns, and unknown unknowns of surveys and sleep
Marcus Shaker, Melissa Moore-Clingenpeel
Page
of 19
Search research articles
Search
Showing results (31-40 of 182) with videos related to
Sort By:
Page
of 19
JAMA Network Open
|
December 21, 2019
Determining Levers of Cost-effectiveness for Screening Infants at High Risk for Peanut Sensitization Before Early Peanut Introduction
Matthew Greenhawt, Marcus Shaker
JAMA Network Open
|
May 4, 2019
Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis
Marcus Shaker, Matthew Greenhawt
Current Opinion in Pediatrics
|
September 1, 2012
An update on hereditary angioedema
Derek Hsu, Marcus Shaker
JAMA Pediatrics
|
June 11, 2019
Benefits of Stock Epinephrine Likely Misestimated-Reply
Marcus Shaker, Matthew Greenhawt
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
May 26, 2019
A primer on cost-effectiveness in the allergy clinic
Marcus Shaker, Matthew Greenhawt
Pediatrics
|
December 2, 2024
Interaction Between Baseline Participant Factors and Treatment Effects Following Peanut Oral Immunotherapy
Alexandra Conway, Marcus Shaker
Pediatrics
|
December 2, 2024
Altered Symptom Perception in Children With Asthma Is Associated With Poor Childhood Opportunity and Adverse Outcomes
Chaitanya Maddukuri, Marcus Shaker
The Journal of Allergy and Clinical Immunology. in Practice
|
May 12, 2018
The Health and Economic Outcomes of Peanut Allergy Management Practices
Marcus Shaker, Matthew Greenhawt
Current Opinion in Allergy and Clinical Immunology
|
August 5, 2016
An update on ocular allergy
Marcus Shaker, Erin Salcone
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
December 4, 2022
The known knowns, known unknowns, and unknown unknowns of surveys and sleep
Marcus Shaker, Melissa Moore-Clingenpeel
Page
of 19